S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
Gili Kenet,
Beatrice Nolan,
Bulent Zulfikar,
Bulent Antmen,
Guy Young,
Jiarui Chi,
Marion Afonso,
Viridiana Cano,
Christian Sussebach,
Shauna Andersson,
Kaan Kavakli
Affiliations
Gili Kenet
1 Tel Aviv University, The National Hemophilia Centre, The Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Aviv, Israel
Beatrice Nolan
2 Children’s Health Ireland at Crumlin, Dublin, Ireland
Bulent Zulfikar
3 Istanbul University Oncology Institute, Division of Pediatric Hematology-Oncology, Istanbul, Turkey
Bulent Antmen
4 Acibadem University, Adana Hospital, Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation Unit, Faculty of Medicine,, Adana, Turkey
Guy Young
5 Hemostasis and Thrombosis Center, Cancer and Blood Diseases Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, LA, CA, United States
Jiarui Chi
6 Sanofi, Bridgewater, New Jersey, United States
Marion Afonso
7 Sanofi, Chilly-Mazarin, France
Viridiana Cano
8 Sanofi, Cambridge, United States
Christian Sussebach
9 Sanofi, Frankfurt am Main, Germany
Shauna Andersson
8 Sanofi, Cambridge, United States
Kaan Kavakli
10 Kaan Department of Haematology, Ege University Faculty of Medicine, Children’s Hospital, Izmir, Turkey
